TMR Research

Monday, 19 December 2016

Market Share Analysis for Pain Management Therapeutics by Therapeutics in 2024

As the world population finds itself on the brink of a chronic pain epidemic, the need to address chronic pain as a public health problem by public health practitioners and scholars is gaining strength. Analysts suggest that nearly 20% of the world’s population presently suffers from chronic pain. Factors such as rising prevalence of chronic diseases, increased number of surgeries, rising geriatric population, and changing lifestyles continue to add nearly 10% new patients to these numbers every passing year.

These factors have triggered the favorable expansion of the global pain management therapeutics market in the past few years and will continue to drive the market at a healthy pace in the next few years. Transparency Market Research suggests that the market will exhibit a 3.7% CAGR over the period between 2016 and 2024. The market, which had a valuation of US$60.2 bn in 2015, is expected to rise to US$83.0 bn by 2024.

Download Complete Healthcare Analytical Brochure:
http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=1059

Cancer Pain Medications Lead Market, but Demand for Back pain to See Most Promising Growth

The WHO states that the number of new cancer cases registered across the globe was nearly 14 mn. Also, over the next two decades, the number of new cancer cases is expected to rise by nearly 70% worldwide. The enormous rise in cancer cases in the past few years naturally makes the disease one of the chief drivers of the pain management therapeutics market and also the key stimulators for the market’s future growth prospects. Transparency Market Research analysts state that the cancer pain management segment accounted for a dominant share of over 28% in the global pain management therapeutics’ market’s overall revenues in 2015.

The segment held the largest share in the revenues of the pain management therapeutics across key regional markets, including North America, Europe, Asia Pacific, and the countries in the Rest of the World. Cancer pain management will continue to account for the largest share in the global pain therapeutics market over the period between 2016 and 2024. However, the segment of back pain management will generate the most promising growth opportunities for the market over the said period. Factors enabling the lucrative growth of the pain management therapeutics market in the back pain indication will be hectic lifestyles and rising geriatric population across the globe.

North America and Europe Emerges as Key Demand Drivers for Pain Management Therapeutics

From a geographical standpoint, the global pain management therapeutics market is dominated by North America and Europe (56% and 26%, respectively, of the global market). These two regional markets collectively accounted for a share of over 80%, with Asia Pacific, the third largest contributor, holding only about 13% of the global market in 2015.

Well-established healthcare infrastructures and high consumption of advanced pain management drugs are the chief factors enabling the excellent growth of the pain management therapeutics markets in these regions. The U.S. held about 96% share of the North America market, positioning the country at a highly commanding position in the global market.

Asia Pacific to Surge Ahead as Key Contributor to Market’s Growth

Over the forecast period, however, the market for pain management therapeutics is expected to witness emergence of the most promising growth opportunities in the Asia Pacific region. The market is expected to expand at the fastest CAGR of 4% over the period between 2016 and 2024. Strengthening economies and rising investments in the healthcare industry, especially in countries such as India and China, are expected to drive the Asia Pacific pain management therapeutics market. Launch and approval of new therapeutic drugs and rising affordability of the population, coupled with the rising awareness regarding the necessity of treating chronic pain will also drive growth of the market in Asia Pacific.

Browse Full Research Report on Pain Management Therapeutics Market:
http://www.transparencymarketresearch.com/pain-management-therapeutics.html

About Us

Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. We have an experienced team of Analysts, Researchers, and Consultants, who us e proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.

Thursday, 15 December 2016

Peptide Receptor Radionuclide Therapy Market by Application 2016 to 2024

Radiopharmaceutical Market: Scope and Trends

This report on the radiopharmaceutical market analyzes the current and future scenario of the global market. Increase in incidence of various diseases, development of new sources for radioisotope production, and rise in demand for nuclear medicine are boosting the radiopharmaceutical market. Increase in incidence of cancer and cardiovascular diseases, growth in awareness about effective use of radiopharmaceuticals, and rise in preference for SPECT and PET scans are some of the factors expected to drive the growth of the global radiopharmaceutical market during the forecast period.

The global radiopharmaceutical market was valued at US$4.7 bn in 2015 and is estimated to reach US$7.4 bn by 2024, expanding at a CAGR of 5.3% from 2016 to 2024.

Download Exclusive Global Strategic Business Report:
http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=213

The radiopharmaceutical market report comprises an elaborate executive summary, which includes market snapshot that provides information about various segments. It also provides information and data analysis of the global market with respect to the segments based on radioisotopes, source, end-user, and geography. A detailed qualitative analysis of drivers and restraints, and opportunities has been provided in the market overview section. Additionally, the section comprises Porters Five Forces Analysis to help understand the competitive landscape in the market. This section also provides market attractiveness analysis in terms of geography and market share analysis by key players, thus presenting a thorough analysis of the overall competitive scenario in the global radiopharmaceutical market.

Radiopharmaceutical Market: Segmentation

Based on radioisotope, the market has been segmented into Technetium-99, Lutetium-177, Rubidium-87, Iodine-123, Yttrium-90, and Gallium-62. Technetium-99 is the most widely used radioisotope across the globe; around 70% of radiopharmaceutical companies depend on Mo-99 to produce Technetium-99, as per the World Nuclear Association. The market segments have been analyzed based on available approved products, cost-effectiveness, and preference for technological systems by physicians and patients. The market size and forecast for each of these segments have been provided for the period from 2014 to 2024, along with their respective CAGRs for the forecast period from 2016 to 2024, considering 2015 as the base year.

Based on source, the radiopharmaceutical market has been segmented into two major categories: nuclear reactors and cyclotrons. The market segments have been extensively analyzed based on increase in demand for radioisotopes for nuclear medicines, availability of radioisotopes and raw materials, radioisotopes short half-life and number of production units used for production of radioisotopes. Different types of end-user utilize radiopharmaceutical products to treat diseases either through imaging techniques or the therapeutics method.

Under the end-user segment, hospitals plays a major role followed by ambulatory surgical centers, diagnostic centers, and others (such as universities, research laboratories, and pathology labs). The market size and forecast in terms of US$ Mn for each segment have been provided for the period from 2014 to 2024. The report also provides the compound annual growth rate (CAGR %) for each market segment for the forecast period from 2016 to 2024, considering 2015 as the base year. Application segment signifies the usage of radiopharmaceutical products through different disease indication such as oncology, cardiology, neurology, nephrology, gastroenterology, immunology and others. Oncology segment is the dominant sector which emphasizes the use of different radioisotopes for treating various cancers and overcome the side effects of therapeutics. Brachytherapy is a sub segment of oncology application which signifies the methods of treating cancer through implants, surgery or radiation technology. The segment is expected to have a significant growth during the forecast period.

Geographically, the global radiopharmaceutical market has been categorized into five major regions and the key countries in the respective region: North America (the U.S. and Canada), Europe (the U.K., Germany, France, Spain, Italy, and Rest of Europe), Asia Pacific (India, Japan, China, Australia, and Rest of Asia Pacific), Latin America (Brazil, Mexico, and Rest of Latin America) and Middle East & Africa (South Africa, Saudi Arabia, and Rest of Middle East & Africa). The market size and forecast for each of these regions and the mentioned countries have been provided for the period from 2014 to 2024, along with their respective CAGRs for the forecast period from 2016 to 2024, considering 2015 as the base year.

Radiopharmaceutical Market: Competitive Landscape

The report also profiles major players in the global radiopharmaceutical market based on various attributes such as company overview, financial overview, product portfolio, business strategies, SWOT analysis, and recent developments. Major players profiled in this report include Advanced Accelerator Applications (AAA), Eckert & Ziegler, GE Healthcare, IBA Radiopharma Solutions, Lantheus Holdings, Inc., Mallinckrodt plc., Nordion, Inc., Siemens Healthineers, and Positron Corporation.

Browse Full Research Report on Radiopharmaceutical Market:
http://www.transparencymarketresearch.com/radiopharmaceuticals-market.html

About Us

Interventional Radiology Market Value Share Analysis By Product Type, 2016 and 2024

Global Interventional Radiology Market: Snapshot

The use interventional radiology procedures is witnessing a huge surge across the globe owing to their minimally invasive nature and benefits such as less recovery time and hospital stay. A number of interventional radiology procedures are being regularly used for the treatment of diseases such as cancer, cardiovascular diseases, and traumatic inquiries, the prevalence of which is rising at an alarming rate globally. The field of interventional radiology also holds immense promise owing to the wide range of applications and technological advancements.

As a result, the global interventional radiology market is poised to observe significant growth in the next few years. Transparency Market Research estimates that market will exhibit a CAGR of 5.8% over the period between 2016 and 2024. If the prediction holds true, the market, which valued at US$13.8 bn in 2015, is expected to reach US$22.9 bn by 2024.

Download Exclusive Global Strategic Business Report:
http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=1337

Rising Numbers of Traumatic Injuries to Boost Demand for Embolization Procedures

In terms of application, the global market for interventional radiology is examined for angiography, balloon angioplasty, embolization, vertebroplasty, biopsy, kyphoplasty, and RF ablation. Of these, the segment of embolization is expected to account for a share of 24.2% of the global market by 2024. The segment also holds the dominant position in the market presently and accounted for a 23.8% of the global market in 2015.

The rising prevalence of traumatic injuries across the globe is expected to drive the increased demand for embolization surgeries worldwide. According to the National Trauma Institute, traumatic injuries account for nearly 41 mn visits to emergency departments and over 2.3 mn hospital admissions. Traumatic injury is also a serious public health issue globally and is expected to lead to an increased demand for embolization surgeries in the near future.

The angiography segment is projected to account for a share of 21.0% in the global market by 2024. The rising global prevalence of strokes and high demand for minimally invasive surgeries will allow the segment to expand at a favorable pace over the forecast period. Biopsy and vertebroplasty-kyphoplasty are relatively smaller segments of the market, with a collective share of nearly 11.8% in the global market in 2015. The segment of biopsy is expected to register a CAGR of 5.6% during the forecast period owing to the increasing prevalence of breast cancer.

Asia Pacific to Lead to Promising Growth Opportunities

With a 38.4% share, the North America interventional radiology market held the top spot in the global market in 2015. Rising demand for minimal invasive procedures and an endless supply of technological advanced devices and equipment are the major factors supporting the growth of the North America market. The x-ray segment gained the leading position in North America in the same year, accounting for over half of the market. Owing to factors such as improvement in technology, rising incidences of a variety of cancers, and well-established healthcare facilities, the North America market for interventional radiology is expected to expand at a swift pace over the next few years as well.

Although North America will continue to account for a higher share in the global interventional radiology market as compared to other regional markets over the forecast period as well, it is expected to lose prominence to the market in Asia Pacific in terms of rate of growth. The Asia Pacific interventional radiology market is expected to exhibit a 7.1% CAGR from 2016 through 2024. Rising prevalence of a variety of cancers, rising geriatric population, improving healthcare facilities, and rising disposable incomes and the relative rise in healthcare spending will play a key role in driving the Asia Pacific interventional radiology market over the said period.

The global interventional radiology market features a consolidated competitive landscape, wherein a relatively small number of companies account for a majority share in the market. Some of the key players operating in the global Interventional Radiology market are Agfa-Gevaert N.V., Fujifilm Holdings Corporation, GE Healthcare, Hitachi Medical Corporation, Hologic, Inc., Medtronic plc., and Philips Healthcare.

Browse Full Research Report on Interventional Radiology Market:
http://www.transparencymarketresearch.com/interventional-radiology-market.html

About Us

Wednesday, 14 December 2016

Global Forensic Technologies Market to Rise at 12.4% CAGR from 2013 to 2019

The global forensic technologies market comprises numerous top players. The segment of DNA profiling in the forensic technologies market is the most dominant segment. The global DNA profiling market is proliferated by the presence of top players such as Bio-Rad, F.Hoffmann La-Roche, and Serva Electrophoresis GmbH, as per Transparency Market Research.

The global forensic technologies market will touch US$17.7 bn by 2019, exhibiting a healthy 12.40% CAGR between 2013 and 2019. In terms of types of forensic technologies/services, the market is segmented into forensic technologies/services delivered namely, DNA profiling, biometrics/fingerprints analysis, chemical (drugs/explosives/toxicology) analysis and firearms identification and analysis. These are used for different purposes such as chemicals (drugs/explosives/toxicology) can be evaluated by emission spectroscopy/spectrophotometry, spectrometry, and chromatography. In addition, DNA profiles are forensically evaluated by DNA chip technology, mtDNA profiling, short tandem repeat (STR), and polymerase chain reaction (PCR) method, among others.

Request a PDF Brochure with Report Analysis:
http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=819

Numerous Technological Initiatives to Bolster North America Forensic Technologies Market

In terms of geography, both Europe and North America held a huge share in the past due to the rising crime rates trailed by numerous technological initiatives being taken toward improving DNA profiling methodology in these regions. However in the coming years, the regions of Asia Pacific and Rest of the World (RoW) together are predicted to hold a share of around 60% by 2019. Hence, the overall market for forensic technologies and services in Asia Pacific is predicted to rise at a whopping 31% CAGR and will account for US$3,891 mn by 2019. On the other hand, RoW is poised to rise at a remarkable CAGR of 35% from 2013 to 2019.

The global forensic technologies market is poised to rise due to the increasing rate of crime globally. The increased level of crime will require an increased employment of forensic services/technologies. In addition, the level of sophistication has increased in crime over the past few years. This type of sophistication in crime is predicted to raise the popularity of new services and technologies that accurately evaluate the newer types of crime. The advent of these new technologies in the global forensic technologies market will further provide impetus to the development of the market, states a TMR analyst.

Decreased Government Spending to Emerge as Roadblock in Market Growth

On the other hand, the market is being hampered by the decreased spending of governments on forensic service and technologies. This happens due to the economy downfall in regions which result in budgetary cuts by governments and thus stop reimbursement and funding of publicly or government funded forensic labs. In addition, a number of regulatory constraints will also imped the growth of the global forensic technologies market

Nonetheless, the rising compliance costs for publicly/government funded forensic labs is a key opportunity seen in the global forensic technologies market” says a TMR analyst.

This information is based on the findings of a report published by Transparency Market Research titled, “Forensic Technologies Market (Physical Crime Forensics, Laboratory Forensics, Portable Forensics, Forensic Tools and Products) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019.”

Browse Full Research Report on Forensic Technologies Market:
http://www.transparencymarketresearch.com/forensics-technology.html

About Us

Tuesday, 13 December 2016

Dental Prosthetics Market Share, Size, Growth & Forecast 2023 Illuminated by New Report

The global dental prosthetics market is consolidated, with the top five companies accounting for 58.8% of the market in 2014. These five companies are Institut Straumann AG, Nobel Biocare Holdings AG, DENTSPLY International, Inc., Biomet 3i, and Zimmer Holdings, Inc. Institut Straumann AG dominates the dental prosthetics market with its strong and wide product portfolio, whereas Nobel Biocare Holdings AG holds a significant share of the pie via strong emphasis on marketing and distribution in emerging economies such as China, Brazil, Eastern Europe, and the Middle East.

The global market for dental prosthetics is estimated to reach a valuation of US$3.5 bn by the end of 2016. Rising at a healthy CAGR of 7.6% during the forecast period 2015–2023, the revenue in the market is expected to reach US$5.88 by the end of 2023.

Request a PDF Brochure with Report Analysis:
http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=556

Segment of Dentures Projected for Strongest Growth Rate

The global market for dental prosthetics can be segmented on the basis of type and geography. By type, the market is segmented into crowns, bridges, veneers, dentures, and others including inlays and onlays. Based on type, crowns was the most prominent segment of the market in 2014, accounting for a share of 49.2%. This segmented is projected to expand at a CAGR of 7.6% during the forecast cast period due to high demand for these products and growing prevalence of dental caries. The segment of dentures is projected to witness the strongest growth in the next few years, fueled by the changing cultural attitude toward edentulism. Aesthetically, edentulism is considered less acceptable than before and hence, increasing pressure to replace missing teeth is contributing to the growth of this segment.

Geographically, Europe served the most prominent demand for dental prosthetics in 2014, accounting for a revenue of US$1.2bn. Europe is expected to remain the most significant regional market for dental prosthetics for the next few years, due to an increase in the prevalence of various oral diseases and high adoption of technologically advanced dental prosthetics. However, Asia Pacific is anticipated to expand at the most robust CAGR during the forecast period, owing to reasons such as rising geriatric population and an increase in investments by market players in this region.

Increase in Oral Diseases Driving Demand

Rise in geriatric population directly affects the growth and development of dental prosthetics as elderly people are most likely to lose their teeth. According to the World Health Organization, the global geriatric population is anticipated to reach 1.5 billion by 2050. An increase in the incidence of oral diseases (oral cancer, pyorrhea, and gingivitis) and the number of dental procedures is further fueling the global market for dental prosthetics. According to WHO, in 2012, 5% to 20% adults aged between 35 years and 44 years were diagnosed with severe periodontal diseases resulting in tooth loss. Growing medical tourism in developing nations is another factor fueling the demand for dental prosthetics.

Conversely, the dental prosthetics market is characterized by intense competition from local manufacturers who offer products at low cost. This is expected to hamper market growth as competition could lead to a fall in prices of products in order to protect market share.

According to the author of the report, “Since the markets in developed regions are saturated, emerging economies such as China, India, South Africa, Brazil, and Mexico offer lucrative new markets. Also, new product, service, and device development will help the players gain ground over their competitors.”

The information presented in this review is based on a Transparency Market Research report, titled, “Dental Prosthetics Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2015–2023.”

Browse Full Research on Drug Dental Prosthetics Market:
http://www.transparencymarketresearch.com/dental-prosthetics-market.html

About Us

North America Drug Device Combination Products Market Revenue by 2019

The global drug device combination products market is a consolidated one with a few well-entrenched companies dominating it. The competition in the market is predicted to heat up further in the near future on account of players channelizing their energies into research and development of products with innovative technologies and improved functionality. The players are also competing with each other to capture the under-penetrated emerging economies. Stringent regulatory norms also induces competition among manufacturers to introduce their products first.

The key players dominating the market are Abbott Laboratories, Inc., Allergan, Inc., Boston Scientific Corporation, CareFusion Corporation and Medtronic, Inc. Abbott Laboratories has enhanced its global presence so far through maximizing business through collaborations and acquisitions and by augmenting its product offerings. Allergan has invested heavily in research and development to come up with innovative products. Boston Scientific has resorted to acquisitions again to strengthen its position.

The global market for drug device combination products was worth US$87.1 bn in 2015 and it is predicted to be worth US$115.1 bn in 2019.

Download Complete Healthcare Industry Analytical Brochure:
http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=1534

Underserved Asia Pacific to be the Engine for Growth

Based upon the type, the global drug device combination products can be segmented into infusion pumps, drug eluting stents, orthopedic combination products, transdermal patches, photosensitizers, wound care combination products, inhalers, intraocular implants, and drug eluting beads. Among them, the inhalers segment dominates the market with the maximum revenue. Going forward, it is expected to retain its dominant share in the market. It revenue in 2015 was US$32.5 bn. The market for transdermal patches followed next.

Geography-wise, North America has surpassed all other regions in terms of revenue generation year-on-year. In the upcoming years, it is predicted to maintain its leading position to reach a value of US$47.6% by 2019, even though it would pare some of its market share in terms of revenue. Europe stands second in terms of revenue generation. However, Asia Pacific is anticipated to steal the show by outshining all other regions. Its market is underpinned by numerous patients seeking treatment for cardiovascular diseases, diabetes, asthma, and obesity management. The drug device combination products market in emerging economies of the Middle East, Latin America and Africa will also enhance the growth in the market.

Growing Elderly Population at the Forefront of Driving Demand

A rising geriatric population at a heightened risk of having cardiovascular diseases, obesity, bone related disorders, various diabetes related disorders, and cancer, is at the forefront of driving growth in the global market for drug device combination products. Such people often suffer from severe fractures and hence require fracture risk assessment before the fracture happens. This is slated to fuel the market growth substantially. Another factor bringing about the growth is the increasing demand for minimally invasive surgeries. Explains the lead analyst of the report, “Minimally invasive surgeries suit the patient’s preferences due to the factors such as reduced post-surgical complications and side effects along with shorter patient recovery span and minimal pain. Therefore, the fact that interventional cardiology involving the implantation of stents and intraocular lenses is a minimally invasive procedure is proving to be a growth driver.”

One factor said to be countering the market’s growth is infections resulting from drug device combination products such as implants and associated product recalls. According to the analyst of the report, “Drug device combination products constantly face threats like product recalls owing to device malfunctions and side effects. Such attributes cause significant revenue losses for the manufacturers and thereby restrain the growth of the market.”

This review is based on the findings of a TMR report titled “Drug Device Combination Products Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013–2019.”

Browse Full Research on Drug Device Combination Products Market:
http://www.transparencymarketresearch.com/drug-device-combination.html

Molecular Diagnostics Market to Register a CAGR of 11.1% from 2013 to 2019 due to Declining Prices

The global molecular diagnostics market is teeming with large and small players involved in developing molecular diagnostics products. This makes the landscape highly fragmented and the competition stiff. Manufacturers are leveraging different strategies to maintain their foothold in the market. Besides investing in research to bring about product differentiation, they are also resorting to mergers and acquisitions to enhance their positions.

Roche Diagnostics is one of the main players operating in the market. It held a dominant share of 31.0% in the market in 2012 by dint of its wide array of product offerings in the areas of oncology, virology, genomics, women’s health, microbiology, and others. Cutthroat competition, however, is resulting in the loss of its market share. Novartis Diagnostics, which is considered a pioneer in the industry and a leader in the blood donor screening segment, followed in the second position in 2012. Other big names operating in the industry are Hologic, Qiagen, Cepheid, Abbott, etc.

The global market for molecular diagnostics is predicted to be worth US$8.66 bn by 2019, predicts a report by Transparency Market Research.

Download Complete Healthcare Analytical Brochure:
http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=1783

Asia Pacific to Clock Maximum Growth Rate due to Prevalence of Chronic Diseases

Technology-wise, the global market for molecular diagnostics can be segmented into polymerase chain reaction (PCR), transcription mediated amplification (TMA), microarray, hybridization (ISH and FISH), next-generation sequencing, and others. Among them, PCR, which finds application in generating millions of copies of DNA sequence through repeated cycles of heating and cooling, holds sway over the market with maximum share. Its market was worth US$2.08 bn in 2015. However, it is the next generation sequencing segment that is slated to outshine all other segments in terms of growth rate during the forecast period.

The global molecular diagnostics market can be segmented geographically into North America, Asia Pacific, Europe, and the Rest of the World. North America has been the dominant market so far and is predicted to maintain its leading share in the coming years too. The TMR report forecasts the market to reach a value of US$3.51 in 2019. Europe follows North America in terms of market share. Growth rate-wise, however, Asia Pacific is poised to overtake the two dominant regions up until 2019. A host of factors such as rising occurrence of chronic maladies, outbreak of H1N1, burgeoning elderly population, prevalence of hepatitis and HIV, economic development, and rising patient awareness are driving the market in the region.

Cancer one of the Main Drivers of Market

One of the main drivers of the global molecular diagnostics market is the alarming increase in the instances of cancer. The World Health Organization (WHO) predicts that the deadly malady will claim 13.1 billion lives from 2012 to 2030. It also warns that annual cancer cases will increase from 14 million in 2012 to 22 million in the next two decades. This would result in further emphasis on research and discovery of biomarkers to detect different types of cancers and thereby lead to a swift uptake of molecular diagnostics tests. Rise in chronic diseases and a growing geriatric population would also boost the market.

A major market deterrent is unfavorable reimbursement policies. “Insurance companies are refraining from reimbursing molecular diagnostic tests due to lack of appropriate coding system. The erstwhile Obama administration stopped paying bills for molecular diagnostic tests. Molecular tests help screen various biomarkers which aid in diagnosis and act as treatment guide for cancer and other diseases. The cost of these tests typically ranges from US$300 to US$3,000 per test and are considered the most important technologies for early detection,” explains the analyst of the report.

This review is based on the findings of a TMR report titled “Molecular Diagnostics Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013–2019.”

Browse Full Research on Molecular Diagnostics Market:
http://www.transparencymarketresearch.com/molecular-diagnostics-industry.html